Rhythm Pharmaceuticals
Rhythm Pharmaceuticals - Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders..
Launch date
Employees
Market cap
€2.8b
Enterprise valuation
€2.6b (Public information from Sep 2024)
Share price
$54.55 RYTM
Boston Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 3.2m | 23.6m | 77.4m | 122m | 178m | 329m |
| % growth | - | - | 649 % | 228 % | 58 % | 46 % | 85 % |
| EBITDA | (137m) | (170m) | (176m) | (168m) | (270m) | (199m) | (144m) |
| % EBITDA margin | - | (5392 %) | (744 %) | (218 %) | (220 %) | (112 %) | (44 %) |
| Profit | (134m) | (69.6m) | (181m) | (185m) | (270m) | (173m) | (38.0m) |
| % profit margin | - | (2207 %) | (766 %) | (239 %) | (221 %) | (97 %) | (12 %) |
| EV / revenue | - | 65.6x | 55.3x | 31.5x | 22.1x | 15.4x | 8.1x |
| EV / EBITDA | -8.3x | -1.2x | -7.4x | -14.5x | -10.0x | -13.8x | -18.6x |
| R&D budget | 90.5m | 104m | 109m | 135m | - | - | - |
| R&D % of revenue | - | 3301 % | 460 % | 174 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$41.0m | Late VC | ||
| N/A | $120m Valuation: $443m | IPO | |
| N/A | $173m | Post IPO Equity | |
* | $37.5m | Post IPO Debt | |
* | $2.9m | Post IPO Equity | |
| Total Funding | €112m | ||
